AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2575021
Drug: Beta adrenergic‐blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta adrenergic‐blocking agents administered in the acute phase of myocardial infarction
Trial: 26208230
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of tranexamic acid (TXA) 15 mg/kg
Trial: 24179982
Drug: Immediate Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Group (immediate implant placement and provisionalisation)
Trial: 24179982
Drug: Delayed Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Group (immediate socket grafting followed by implant placement and provisionalisation after 4 months)
Trial: 19567910
Drug: Amoxicillin 40
RxNorm normalized name: amoxicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 40 mg/kg/day in three doses
Trial: 16546635
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics (Group Ab: 2.4 mIU of intramuscular penicillin G benzathine or 5-7 day regimen of oral clindamycin if allergic)
Trial: 16546635
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotics (Group non-Ab)
Trial: 10662479
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B plus G-CSF (1 mg/kg daily plus 3 to 5 micrograms/kg daily)
Trial: 10662479
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B monotherapy (1 mg/kg daily)
Trial: 10662479
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B plus G-CSF
Trial: 10662479
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B monotherapy
Trial: 26319283
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioural therapy (delivered once a week for 10 weeks)
Trial: 26319283
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavioural therapy
Trial: 9359660
Drug: Hydroxyurea and
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea and didanosine (ddI) combination treatment
Trial: 7946687
Drug: Ioxaglate 320
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate 320 mg I/ml
Trial: 9990415
Drug: Tretinoin 0.05%
RxNorm normalized name: TRETINOIN 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.05% cream
Trial: 9748886
Drug: Piracetam (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (12 g i.v. bolus) with Dextran 40 (500 ml daily)
Trial: 9748886
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Dextran 40 (500 ml daily)
Trial: 7827714
Drug: Lidocaine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (200 to 250 mg loading and 3 mg/min maintenance infusions)
Trial: 7827714
Drug: Procainamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (1 gm loading and 3 to 4 mg/min maintenance infusions)
Trial: 22752958
Drug: Modified-release prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release prednisone (5 mg)
Trial: 22752958
Drug: Standard prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prednisolone (5 mg)
Trial: 28969890
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri strain DSM 17938 (5 × 10^8 colony-forming units daily)
Trial: 26159012
Drug: Danlong Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danlong Oral Liquid (DOL), 10 mL each time, 3 times per day for 7 days
Trial: 26159012
Drug: Kechuanning Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kechuanning Oral Liquid (KOL), 10 mL each time, 3 times per day for 7 days
Trial: 21982673
Drug: Oral informed
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral informed consent
Trial: 21982673
Drug: All formats
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formats (oral, written, video)
Trial: 19356104
Drug: Nevirapine/Efavirenz treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine/Efavirenz treatment (follow-up patients)
Trial: 17069471
Drug: RS‐86 (M1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS‐86 (M1 mAChR agonist)
Trial: 9397080
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg twice daily
Trial: 6340971
Drug: Sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 200 mg twice daily
Trial: 8635369
Drug: Triazolam, 0.25
RxNorm normalized name: Triazolam, 0.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam, 0.25 mg
Trial: 3742936
Drug: Flurazepam (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurazepam (dose not specified)
Trial: 29669442
Drug: Targeted Interdisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME)
Trial: 24983776
Drug: Ovarian artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian artery velocimetry in women needing HCG administration
Trial: 20730517
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n=19)
Trial: 10534247
Drug: 10,000 U
RxNorm normalized name: Erwinaze 10,000 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 U BoNT/B (NeuroBloc) administered in a single session into two to four clinically involved muscles.
Trial: 6578788
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment with comprehensive support and a 24-hour crisis service
Trial: 29941991
Drug: IP6 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP6 supplements for 3 months
Trial: 26211605
Drug: Ergocalciferol (vitamin
RxNorm normalized name: ergocalciferol (vitamin D2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (vitamin D2) 50,000 IU twice weekly for 8 weeks
Trial: 26211605
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) 50,000 IU weekly for 8 weeks
Trial: 17268068
Drug: FK506 (Tacrolimus);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 (Tacrolimus); dosage and duration not specified
Trial: 17268068
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (MG(FK-)); no FK506 administration
Trial: 17268068
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Healthy subjects); no FK506 administration
Trial: 16119511
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cefepime 4 g/d
Trial: 16119511
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of cefepime 2 x 2 g
Trial: 9385488
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg QD
Trial: 9385488
Drug: lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 15 mg QD
Trial: 9385488
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg QD
Trial: 9385488
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg QID
Trial: 8187316
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (Group 1)
Trial: 8187316
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg three times daily (Group 2)
Trial: 8187316
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg three times daily (Group 3)
Trial: 3108170
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (900-1,200 mg/day for 4 days)
Trial: 30395486
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atomoxetine plus 5 mg oxybutynin (ato-oxy)
Trial: 30395486
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atomoxetine
Trial: 30395486
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oxybutynin
Trial: 21293249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of losartan and mizoribine (n = 34)
Trial: 12664518
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg/kg
Trial: 16717306
Drug: Morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.2 mg/kg
Trial: 14687095
Drug: Remifentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.0 micro g.kg‐1
Trial: 14687095
Drug: Remifentanil 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2.0 micro g.kg‐1
Trial: 14687095
Drug: Remifentanil 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3.0 micro g.kg‐1
Trial: 14687095
Drug: Control (Propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Propofol and Mivacurium 0.2 mg.kg‐1)
Trial: 14687095
Drug: Remifentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.0 micro g.kg‐1 and Control
Trial: 11352853
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg once daily for 28 days
Trial: 9205820
Drug: Draflazine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draflazine 0.25 mg
Trial: 9205820
Drug: Draflazine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draflazine 0.5 mg
Trial: 7650223
Drug: Draflazine 1
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Draflazine 1 mg
Trial: 9205820
Drug: Draflazine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draflazine 1.5 mg
Trial: 9205820
Drug: Draflazine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Draflazine 2.5 mg
Trial: 9205820
Drug: Draflazine 1
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Draflazine 1 mg followed by 1 mg h‐1 infusion
Trial: 8025138
Drug: Myocardial revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myocardial revascularization (surgical therapy)
Trial: 29562405
Drug: Penehyclidine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penehyclidine hydrochloride 0.05 mg/kg
Trial: 27600995
Drug: gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine + erlotinib (G + E)
Trial: 27600995
Drug: gemcitabine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine + placebo (G + P)
Trial: 25302067
Drug: Tianjiu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianjiu therapy for 1 year
Trial: 25302067
Drug: Tianjiu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianjiu therapy for 2 years
Trial: 31881232
Drug: Egg oral
RxNorm normalized name: Egg Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg oral immunotherapy (OIT)
Trial: 12691271
Drug: Braun Oral-B
RxNorm normalized name: bran Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral-B 3D Excel (D17)
Trial: 9820263
Drug: Yoga-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga-based intervention consisting of 11 yoga postures, given twice weekly for 8 weeks
Trial: 9820263
Drug: Wrist splint
RxNorm normalized name: Wrist Splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist splint to supplement current treatment
Trial: 8562352
Drug: Four-drug chemotherapy
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug chemotherapy regimen (ECMV: etoposide, cyclophosphamide, methotrexate, vincristine)
Trial: 8562352
Drug: Two-drug chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug chemotherapy regimen (EV: etoposide and vincristine)
Trial: 8562352
Drug: Four-drug chemotherapy
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug chemotherapy regimen (ECMV)
Trial: 8562352
Drug: Two-drug chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug chemotherapy regimen (EV)
Trial: 2012514
Drug: Controlled-release Sinemet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release Sinemet (levodopa/carbidopa)
Trial: 30616671
Drug: Regional adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional adipose tissue grafting (AT-G)
Trial: 14634808
Drug: Action effects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action effects with target-compatible color effects (e.g., blue word -> left key -> blue patch)
Trial: 1662562
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg once daily
Trial: 2758453
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg diltiazem
Trial: 1233072
Drug: Salbutamol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (8 mg) administered twice daily as a sustained release formulation
Trial: 1233072
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 mug) administered by aerosol
Trial: 31405750
Drug: N-acetylcysteine rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine rinse (10% solution, 2500 mg daily, 5 times daily during radiotherapy and 2 weeks post-radiotherapy)
Trial: 23222413
Drug: Ginger (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (2.0 g/day)
Trial: 18449063
Drug: Levofloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (10 mg/kg twice daily)
Trial: 18449063
Drug: Amoxicillin/clavulanate (14:1;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (14:1; amoxicillin 45 mg/kg twice daily)
Trial: 18449063
Drug: Levofloxacin and
RxNorm normalized name: levofloxacin and ornidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin and Amoxicillin/clavulanate
Trial: 10866907
Drug: ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 0.1 mg/kg IV injection
Trial: 10866907
Drug: placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (normal saline) IV injection
Trial: 10866907
Drug: diphenhydramine 30
RxNorm normalized name: pseudoephed/diphenhydramine 30 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diphenhydramine 30 mg IV injection
Trial: 9358912
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of 25,000 IU vitamin A and 30 mg beta-carotene
Trial: 8451310
Drug: 560 ml
RxNorm normalized name: ALCOHOL 392 mL in 560 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 ml of CMW
Trial: 8451310
Drug: 560 ml
RxNorm normalized name: ALCOHOL 392 mL in 560 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 560 ml of APM-sweetened soft drink (340 mg APM)
Trial: 8451310
Drug: 280 ml
RxNorm normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 ml of APM-sweetened mineral water (340 mg APM)
Trial: 8451310
Drug: 280 ml
RxNorm normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 ml of carbonated mineral water (CMW)
Trial: 8451310
Drug: 280 ml
RxNorm normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 ml of CMW with 340 mg of encapsulated APM
Trial: 2870944
Drug: Pipothiazine palmitate
RxNorm normalized name: Pipothiazine palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipothiazine palmitate (PPT) 100 mg alternating with placebo
Trial: 2870944
Drug: Flupenthixol decanoate
RxNorm normalized name: flupenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol decanoate (FPX) 40 mg
Trial: 30440907
Drug: RAPAEL Smart
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAPAEL Smart Board therapy (30 minutes a day, 5 days per week, for 4 weeks) in addition to traditional treatments (30 minutes of functional arm movement therapy)
Trial: 30440907
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (two 30-minute sessions, 5 days per week, for 4 weeks)
Trial: 22806823
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg
Trial: 21265123
Drug: Complex preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex preventive therapy including wobenzym
Trial: 9469682
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol (HDL) 5 mg plus lorazepam (LZ) 2 mg (9 patients)
Trial: 9469682
Drug: Intramuscular lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular lorazepam (LZ) 2 mg (11 patients)
Trial: 15730346
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg daily)
Trial: 25616927
Drug: Bivalirudin (BIV-LOW)
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin (BIV-LOW) at 0.25 mg/kg/h
Trial: 25616927
Drug: Bivalirudin (BIV-PCI)
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin (BIV-PCI) at 1.75 mg/kg/h
Trial: 25616927
Drug: Heparin ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin ± GPI
Trial: 23505929
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg oral dose administered 4 hours before the match)
Trial: 23505929
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered to the control group)
Trial: 21382864
Drug: Snoezelen room
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Snoezelen room sessions (30 minutes, twice a week for six weeks)
Trial: 19112801
Drug: Active gel
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active gel (topical gel containing growth factors, cytokines, and soluble matrix proteins)
Trial: 14653030
Drug: Therapeutic angiogenesis
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic angiogenesis using recombinant growth-factor protein application or growth factor gene therapy.
Trial: 14653030
Drug: Angiogenic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiogenic therapy (specifics not provided).
Trial: 22515360
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Levofloxacin 500 mg once daily for 7 days
Trial: 22515360
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Tetracycline 500 mg four times daily for 14 days
Trial: 20513227
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release methylphenidate (MPH)
Trial: 20513227
Drug: Twice-daily immediate-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily immediate-release methylphenidate (MPH)
Trial: 16410734
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with diuretic indapamide and angiotensin-converting enzyme inhibitor perindopril if required
Trial: 10685583
Drug: Ground-level oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground-level oxygen (GLO) treatment for 2 hours